Skip to main content

Table 3 Crude and adjusted hazard ratios for the association between variable and the risk of NTM infection during all follow-up period

From: The risk of nontuberculous mycobacterial infection in patients with Sjögren’s syndrome: a nationwide, population-based cohort study

  Univariate analysis Model A Model B
  HR (95%CI) HR (95%CI) HR (95%CI)
Group
 Non- SS Reference Reference Reference Reference Reference Reference
 SS 7.66 (2.36–24.94) 3.17 (0.70–14.24)   
 SS treated without immunosuppressants 2.47 (0.31–19.53)    1.95 (0.24–15.68)
 SS treated with immunosuppressants 25.45 (6.88–94.05)    17.77 (4.53–69.61)
Age
  < 50 years Reference Reference Reference Reference Reference Reference
  ≥ 50 years 1.82 (0.50–6.60) 1.63 (0.43–6.19) 1.64 (0.43–6.24)
Gender
 Female Reference Reference Reference Reference Reference Reference
 Male 3.50 (1.08–11.36) 3.34 (1.02–10.96) 3.27 (0.99–10.74)
CCI group
 0 Reference Reference Reference Reference Reference Reference
  ≥ 1 1.55 (0.48–5.04) 0.97 (0.29–3.30) 1.00 (0.30–3.41)
Medications
 Immunosuppressants 13.74 (3.78–49.94) 4.89 (0.94–25.33)   
 Methotrexate 18.74 (4.15–84.56)     
 Azathioprin 21.26 (4.71–95.91)     
 Cyclophosphamide 27.86 (6.18–125.70)     
 Steroid 3.94 (1.08–14.37) 2.65 (0.68–10.26) 2.72 (0.70–10.55)
  1. Abbreviations: SS Sjögren’s Syndrome, CCI Charlson cormorbidity